Nautilus Biotechnology, Inc.

# Signal Note: Perceptive Advisors Initiates $24.6M Position in NAUT Perceptive's entry into Nautilus—a proteomics platform company focused on discovering novel drug targets through mass spectrometry—signals conviction in the emerging field of unbiased protein discovery as a source of differentiated early-stage assets. Edelman's track record backing clinical-stage biotech suggests confidence in Nautilus's scientific approach, though near-term catalysts will hinge on target validation data and partnership announcements rather than clinical readouts. Key inflection points to monitor: proof-of-concept studies in oncology/immunology and potential pharma collaborations that could de-risk platform validation.